Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
1(11%)
Results Posted
50%(3 trials)
Terminated
1(11%)

Phase Distribution

Ph not_applicable
2
22%
Ph phase_3
1
11%
Ph phase_4
4
44%

Phase Distribution

0

Early Stage

0

Mid Stage

5

Late Stage

Phase Distribution7 total trials
Phase 3Large-scale testing
1(14.3%)
Phase 4Post-market surveillance
4(57.1%)
N/ANon-phased studies
2(28.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(6)
Terminated(1)

Detailed Status

Completed6
Terminated1
Enrolling by invitation1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
85.7%
Most Advanced
Phase 4

Trials by Phase

Phase 31 (14.3%)
Phase 44 (57.1%)
N/A2 (28.6%)

Trials by Status

terminated111%
enrolling_by_invitation111%
completed667%
recruiting111%

Recent Activity

1 active trials
Showing 5 of 9
enrolling_by_invitationphase_4

Pilot Study of StudyU for N-of-1 Trials in HFrEF Patients (N-of-1 App)

NCT07252310
completednot_applicable

The Treatment of Hepatocirrhosis and Portal Hypertension

NCT02778425
completedphase_4

Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF

NCT04757584
completedphase_4

Impact of Beta-blockers on Physical Function in HFpEF

NCT04767061
recruiting

Evaluation and Management of Cardio Toxicity in Oncologic Patients

NCT02818517
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07252310Phase 4

Pilot Study of StudyU for N-of-1 Trials in HFrEF Patients (N-of-1 App)

Enrolling By Invitation
NCT02778425Not Applicable

The Treatment of Hepatocirrhosis and Portal Hypertension

Completed
NCT04757584Phase 4

Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF

Completed
NCT04767061Phase 4

Impact of Beta-blockers on Physical Function in HFpEF

Completed
NCT02818517

Evaluation and Management of Cardio Toxicity in Oncologic Patients

Recruiting
NCT02200822Phase 4

Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients

Completed
NCT03291145Not Applicable

Exploring Mechanisms and Morphology of QT Interval Prolongation

Completed
NCT00953212Phase 3

Prophylaxis to Reduce Postoperative Atrial Fibrillation in Cardiac Surgery

Completed
NCT02240641

Effect of Caldine® on Renal Function in Balanced Hypertension

Terminated

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9